Clinical Report: Could Red-Light Therapy Change Myopia Care?
Overview
Repeated low-level red-light therapy may reduce myopia progression in pediatric patients over 12 months, with treatment effects increasing over time. Significant improvements were noted in spherical equivalent refraction, axial length, and choroidal thickness compared to controls.
Background
Incorporate specific statistics or studies that emphasize the urgency of addressing myopia.
Data Highlights
Outcome
12 Months Improvement
Spherical Equivalent Refraction
0.68 diopters
Axial Length
-0.30 mm
Choroidal Thickness
+27 µm
Key Findings
28 randomized controlled trials with 3,573 pediatric patients were included in the analysis.
At 12 months, patients with high myopia experienced the greatest benefit, with a 0.90-diopter improvement.
Short-term structural parameters remained stable, with no severe treatment-related adverse events reported.
Some patients experienced transient visual disturbances and discomfort, leading to treatment discontinuation.
Evidence for improvements in spherical equivalent refraction and choroidal thickness was rated as moderate certainty.
Clinical Implications
Clinicians should consider repeated low-level red-light therapy as a potential option for managing myopia in pediatric patients, particularly for those with higher baseline myopia. However, the need for long-term safety data and careful patient selection remains critical.
Conclusion
Repeated low-level red-light therapy appears to be an effective intervention for slowing myopia progression in children, with increasing benefits over time. Further research is necessary to assess long-term safety and efficacy.
